IRIS
RONCATO, Rossana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.794
AS - Asia 1.384
EU - Europa 632
SA - Sud America 242
AF - Africa 44
OC - Oceania 1
Totale 4.097
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.743
SG - Singapore 707
CN - Cina 279
BR - Brasile 200
HK - Hong Kong 164
IT - Italia 135
RU - Federazione Russa 96
DE - Germania 86
VN - Vietnam 71
IN - India 49
GB - Regno Unito 48
IE - Irlanda 48
KR - Corea 39
FR - Francia 34
FI - Finlandia 33
CA - Canada 26
NL - Olanda 25
UA - Ucraina 21
AT - Austria 20
MX - Messico 20
AR - Argentina 18
CH - Svizzera 16
TG - Togo 15
PL - Polonia 14
SE - Svezia 14
TR - Turchia 14
BD - Bangladesh 12
CZ - Repubblica Ceca 12
ES - Italia 12
ZA - Sudafrica 8
ID - Indonesia 7
JP - Giappone 7
EC - Ecuador 6
CO - Colombia 5
IQ - Iraq 5
PK - Pakistan 5
TN - Tunisia 5
LT - Lituania 4
MA - Marocco 4
AE - Emirati Arabi Uniti 3
BE - Belgio 3
CL - Cile 3
EG - Egitto 3
KE - Kenya 3
OM - Oman 3
RO - Romania 3
SA - Arabia Saudita 3
UY - Uruguay 3
VE - Venezuela 3
AO - Angola 2
CR - Costa Rica 2
DK - Danimarca 2
DZ - Algeria 2
KZ - Kazakistan 2
PE - Perù 2
TH - Thailandia 2
UZ - Uzbekistan 2
AL - Albania 1
AM - Armenia 1
AU - Australia 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CI - Costa d'Avorio 1
CY - Cipro 1
DM - Dominica 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
JM - Giamaica 1
NI - Nicaragua 1
NO - Norvegia 1
NP - Nepal 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SY - Repubblica araba siriana 1
Totale 4.097
Salva come PNG Salva come JPEG
Città #
Singapore 265
Ashburn 231
Hong Kong 163
Beijing 122
Chicago 121
Los Angeles 114
Boardman 75
Fairfield 69
Chandler 68
Salt Lake City 57
Dallas 51
Dublin 47
Houston 41
Hefei 40
Munich 40
Seoul 39
Wilmington 39
Woodbridge 38
Cambridge 32
Elk Grove Village 30
New York 30
Seattle 30
Ho Chi Minh City 26
Redondo Beach 24
Buffalo 23
Hanoi 22
Tampa 22
São Paulo 19
London 17
Montreal 16
Zurich 16
Lomé 15
Nuremberg 15
Ann Arbor 14
Frankfurt am Main 14
Miami 14
Santa Clara 14
Dearborn 13
Pune 13
Turku 13
Vienna 13
Denver 12
Ogden 12
Warsaw 12
Brno 10
Genoa 10
Stockholm 10
Amsterdam 9
Helsinki 9
Princeton 9
Sterling 9
Arezzo 8
Brooklyn 8
Chennai 8
Dulles 8
Lappeenranta 8
Milan 8
Redmond 8
Hyderabad 7
Lauterbourg 7
Mumbai 7
Phoenix 7
Poplar 7
Tokyo 7
Udine 7
Jacksonville 6
Mexico City 6
Portsmouth 6
Rome 6
Ankara 5
Belluno 5
Belo Horizonte 5
Des Moines 5
Detroit 5
Düsseldorf 5
Guangzhou 5
Guarulhos 5
Lancaster 5
Naples 5
Rio de Janeiro 5
Boston 4
Brasília 4
Cormons 4
Deiva Marina 4
Guayaquil 4
Izmir 4
Johannesburg 4
Kansas City 4
Las Vegas 4
New Delhi 4
Orem 4
Querétaro 4
Xi'an 4
Zoppola 4
Atlanta 3
Baghdad 3
Bengaluru 3
Brussels 3
Charlotte 3
Codroipo 3
Totale 2.425
Salva come PNG Salva come JPEG
Nome #
Pharmacogenomics of Targeted Agents for Personalization of Colorectal Cancer Treatment 536
Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) 154
A TGF-β associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer 126
Estimating the Effectiveness of DPYD Genotyping in Italian Individuals Suffering from Cancer Based on the Cost of Chemotherapy-Induced Toxicity 125
The use of pharmacogenetics to increase the safety of colorectal cancer patients treated with fluoropyrimidines 109
Abstract PD10-01: Impact of ESR1 mutations on Selective Estrogen Receptor Degraders and Modulators: an integrated liquid-biopsy and pharmacodynamics approach 103
DPYD gene activity score (GAS) predicts dose-limiting toxicity in fluoropyrimidine-treated colorectal cancer patients 101
SMAD3 Host and Tumor Profiling to Identify Locally Advanced Rectal Cancer Patients at High Risk of Poor Response to Neoadjuvant Chemoradiotherapy 97
Is ctDNA ready to outpace imaging in monitoring early and advanced breast cancer? 95
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure 92
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients 91
Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer 89
Rare genetic variant burden in DPYD predicts severe fluoropyrimidine-related toxicity risk 87
An Integrated Pharmacological Counselling Approach to Guide Decision-Making in the Treatment with CDK4/6 Inhibitors for Metastatic Breast Cancer 83
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study 82
FARMAPRICE: A Pharmacogenetic Clinical decision support system for precise and Cost-Effective Therapy 79
The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice 77
Correction: Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy (Cell Death & Disease, (2022), 13, 4, (398), 10.1038/s41419-022-04741-9) 71
Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy 67
NAFLD-Related Hepatocarcinoma: The Malignant Side of Metabolic Syndrome 66
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 64
IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm 62
Therapeutic Monitoring of Palbociclib, Ribociclib, Abemaciclib, M2, M20, and Letrozole in Human Plasma: A Novel LC-MS/MS Method 62
A Systematic Review and a Meta-Analysis Comparing Prophylactic and Therapeutic Low Molecular Weight Heparins for Mortality Reduction in 32,688 COVID-19 Patients 61
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 61
Lipid rafts as viral entry routes and immune platforms: A double-edged sword in SARS-CoV-2 infection? 60
LC-MS/MS Method for the Quantification of PARP Inhibitors Olaparib, Rucaparib and Niraparib in Human Plasma and Dried Blood Spot: Development, Validation and Clinical Validation for Therapeutic Drug Monitoring 59
Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis 58
Implementation of preemptive testing of a pharmacogenomic panel in clinical practice: Where do we stand? 58
Clinical Benefits and Utility of Pretherapeutic DPYD and UGT1A1 Testing in Gastrointestinal Cancer 57
Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation? 57
The use of therapeutic drug monitoring to highlight an over-looked drug-drug interaction leading to imatinib treatment failure 56
Therapeutic drug monitoring for the cancer patient: challenges and opportunities 56
The challenge of molecular selection in liver-limited metastatic colorectal cancer for surgical resection: a systematic review and meta-analysis in the context of current and future approaches 55
Cisplatin resistance can be curtailed by blunting Bnip3-mediated mitochondrial autophagy 55
Pharmacogenetic score predicts overall survival, progression-free survival and platinum sensitivity in ovarian cancer 54
Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice 53
European association for clinical pharmacology and therapeutics young clinical pharmacologists working group: a cornerstone for the brighter future of clinical pharmacology 52
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype 52
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach 52
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS) 51
mHealth Apps Available in Italy to Support Health Care Professionals in Antimicrobial Stewardship Implementation: Systematic Search in App Stores and Content Analysis 51
Cancer Pharmacogenetics: perspective on newly discovered and implemented predictive biomarkers 51
Genetic biomarkers for hepatocellular cancer risk in a caucasian population 48
Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study 48
Inositol and Non-Alcoholic Fatty Liver Disease: A Systematic Review on Deficiencies and Supplementation 48
The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity 47
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions 46
Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines 45
Pregnane X receptor, constitutive androstane receptor and hepatocyte nuclear factors as emerging players in cancer precision medicine 43
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma 43
Improving decision making on DPYD and UGT1A1*28 patients' profiling with an innovative reimbursement strategy 42
Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice 40
Ten-year experience with pharmacogenetic testing for DPYD in a national cancer center in Italy: Lessons learned on the path to implementation 39
Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI 39
Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients 36
Exploring pharmacokinetic variability of palbociclib in HR+/HER2- metastatic breast cancer: a focus on age, renal function, and drug–gene interactions 34
Clinical relevance and methodological approach for the assessment of drug–drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF) 30
Uptake of DPYD and UGT1A1 testing in Italy and adherence to pharmacogenetic guidelines: A 5-year perspective from an EQA provider 18
Quantification of Letrozole, Palbociclib, Ribociclib, Abemaciclib, and Metabolites in Volumetric Dried Blood Spots: Development and Validation of an LC-MS/MS Method for Therapeutic Drug Monitoring 17
Integration of germline pharmacogenomic burden to predict fluoropyrimidine-related toxicity – A secondary analysis of the PREPARE trial 13
Totale 4.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.049
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20.049
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202175 0 0 0 0 0 11 28 11 8 5 7 5
2021/202266 3 5 0 4 2 2 11 0 4 10 14 11
2022/2023318 9 3 4 77 59 70 0 22 45 4 9 16
2023/2024339 31 19 11 4 39 40 21 15 19 31 25 84
2024/20251.233 53 87 42 37 85 69 91 57 126 99 221 266
2025/20261.990 456 408 403 223 320 180 0 0 0 0 0 0
Totale 4.303